ATE199260T1 - Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren - Google Patents

Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren

Info

Publication number
ATE199260T1
ATE199260T1 AT94927602T AT94927602T ATE199260T1 AT E199260 T1 ATE199260 T1 AT E199260T1 AT 94927602 T AT94927602 T AT 94927602T AT 94927602 T AT94927602 T AT 94927602T AT E199260 T1 ATE199260 T1 AT E199260T1
Authority
AT
Austria
Prior art keywords
peptides
hiv
nucleotide sequences
sequences
fusion
Prior art date
Application number
AT94927602T
Other languages
English (en)
Inventor
Hermann Katinger
Thomas Muster
Original Assignee
Polymun Scient Immunbio Forsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scient Immunbio Forsch filed Critical Polymun Scient Immunbio Forsch
Application granted granted Critical
Publication of ATE199260T1 publication Critical patent/ATE199260T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94927602T 1993-09-11 1994-09-12 Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren ATE199260T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93114631 1993-09-11
PCT/EP1994/003039 WO1995007354A1 (en) 1993-09-11 1994-09-12 Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains

Publications (1)

Publication Number Publication Date
ATE199260T1 true ATE199260T1 (de) 2001-03-15

Family

ID=8213253

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927602T ATE199260T1 (de) 1993-09-11 1994-09-12 Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren

Country Status (15)

Country Link
EP (1) EP0725825B1 (de)
JP (1) JPH09502348A (de)
CN (1) CN1135237A (de)
AT (1) ATE199260T1 (de)
AU (1) AU682893B2 (de)
BR (1) BR9407531A (de)
CA (1) CA2171544C (de)
CZ (1) CZ287808B6 (de)
DE (1) DE69426725T2 (de)
ES (1) ES2156902T3 (de)
HU (1) HU219507B (de)
PT (1) PT725825E (de)
RU (1) RU2181379C2 (de)
UA (1) UA43350C2 (de)
WO (1) WO1995007354A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0822941B1 (de) * 1995-04-19 2002-06-12 Polymun Scientific Immunbiologische Forschung GmbH Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe
US6319890B1 (en) 1996-12-30 2001-11-20 Manfred P. Dierich Inhibition of binding of complement Factor H
AU751358B2 (en) * 1998-03-23 2002-08-15 Trimeris Inc. Methods and compositions for peptide synthesis
US6482928B1 (en) 1999-04-13 2002-11-19 Aventis Pasteur Limited And University Of Toronto Fab′-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5
CN1172717C (zh) * 2000-08-18 2004-10-27 清华大学 一种治疗艾滋病的药物及其制备方法
FR2851165A1 (fr) * 2003-02-19 2004-08-20 Aventis Pasteur Antigene derivant de l'helice c de la proteine gp41
WO2006110831A2 (en) 2005-04-12 2006-10-19 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP1754715A1 (de) 2005-08-19 2007-02-21 Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut Impfstoff auf Basis virusneutralisierender Antikörper
JP2010523676A (ja) 2007-04-13 2010-07-15 デューク ユニバーシティ ヒト免疫不全ウイルスに対する中和抗体を誘導する方法
EP2393509A1 (de) * 2009-02-06 2011-12-14 Mymetics Corporation Gp41-spaltung
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570357B1 (de) * 1992-05-14 1997-06-25 Polymun Scientific Immunbiologische Forschung GmbH Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same

Also Published As

Publication number Publication date
PT725825E (pt) 2001-08-30
JPH09502348A (ja) 1997-03-11
HU219507B (hu) 2001-04-28
BR9407531A (pt) 1997-08-26
HUT76102A (en) 1997-06-30
CA2171544C (en) 2003-06-24
AU7696594A (en) 1995-03-27
HU9600587D0 (en) 1996-05-28
UA43350C2 (uk) 2001-12-17
ES2156902T3 (es) 2001-08-01
CZ74196A3 (en) 1996-07-17
CN1135237A (zh) 1996-11-06
DE69426725T2 (de) 2001-09-06
AU682893B2 (en) 1997-10-23
EP0725825A1 (de) 1996-08-14
WO1995007354A1 (en) 1995-03-16
CZ287808B6 (en) 2001-02-14
EP0725825B1 (de) 2001-02-21
DE69426725D1 (de) 2001-03-29
RU2181379C2 (ru) 2002-04-20
CA2171544A1 (en) 1995-03-16

Similar Documents

Publication Publication Date Title
DE3588251T2 (de) DNS-Fragmente des GAG-Gens von LAV
CA2392877A1 (en) Improvements in or relating to immune responses to hiv
EP0339504A3 (de) Menschliches immunoinsuffizientes Virus (HIV) env-codiertes Peptid, welches im Stande ist, die HIV hemmenden Antikörper bei Säugetieren hervorzurufen
CA2164818A1 (en) Tandem synthetic hiv-1 peptides
ATE199260T1 (de) Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren
DE69535035D1 (de) Präparate zur verabreichung von genetischem material
CA2107732A1 (en) Retrovirus from the hiv group and its use
BRAND et al. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles
JP2743164B2 (ja) Aidsの原因ウィルスの糖蛋白質をコードするウィルスベクター及び組換えdna、該ベクターにより感染された細胞培養物、並びに抗体
FR2700169B1 (fr) Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
JP2004509601A5 (de)
EP0519001B1 (de) Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt
JPH07110877B2 (ja) Hiv逆転写酵素に対する細胞毒性t細胞免疫を刺激するペプチド
Le Blanc et al. HTLV-1 structural proteins
WO1993018055B1 (en) Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160
RU96108781A (ru) Пептиды, создающие нейтрализующие антитела к генетически дифергентным штаммам вич-1
CA2084386A1 (en) Hiv antigen
WO1993003766A1 (en) Multiple antigen peptides for use as hiv vaccines
US6379679B1 (en) Multiple branch peptide construction
Wang et al. DNA inoculation induces cross clade anti-HIV-1 responses
EP0469089A1 (de) Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
WO1998037089A3 (en) Matrix derived anti-hiv peptides and transdominant proteins
FR2607518A1 (fr) Vecteur viral et adn recombinant codant pour la proteine p25 du virus agent causal du s.i.d.a., culture cellulaire infectee, proteine obtenue, vaccin et anticorps obtenus
Vogt et al. Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins
US7285621B2 (en) Multiple branch peptide construction

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties